Cefteram
Chemical compound
- J01DD18 (WHO)
- In general: ℞ (Prescription only)
- (6R,7R)-7-([(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino)-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 82547-58-8
- 6537431
- 4576594
- 74CQ4Q3N63
- D07655
- ChEMBL2105953
- DTXSID7048821
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3nc(sc3)N)Cn4nc(nn4)C)C(=O)O
Cefteram (INN) is a third-generation cephalosporin antibiotic.[1]
Synthesis
The reaction of 7-aminocephalosporanic acid (1) with the methyl-substituted tetrazole (2) gives the intermediate (3). Protection with diazodiphenylmethane (4) produces (5). Amide formation with the thiazole carboxylic acid (6) gives (7), which is deprotected with trifluoroacetic acid to yield cefteram.[2][3]
References
- ^ Yamaguchi K, Ohno A, Takahashi S, Hayashi M, Yamanaka K, Hirakata Y, Mitsuyama J (January 1998). "[In vitro antibacterial activities of cefteram and other beta-lactam agents against recent clinical isolates]". The Japanese Journal of Antibiotics. 51 (1): 11–25. PMID 9557273.
- ^ "Cefteram". chemdrug.com. Retrieved 2024-07-03.
- ^ US patent 4489072, Hiroshi Sadaki, et al., issued 1984-12-18, assigned to Toyama Chemical Co Ltd
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Lipopeptides |
|
---|---|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e